Matinas BioPharma Holdings (MTNB) Amortization of Deferred Charges (2019 - 2021)
Matinas BioPharma Holdings (MTNB) reported Amortization of Deferred Charges of $115589.0 for Q2 2021, down 3.68% year-over-year from $120000.0 in Q2 2020, and down 8.91% quarter-over-quarter from $126896.0 in Q1 2021.
Matinas BioPharma Holdings (MTNB) Amortization of Deferred Charges (2019 - 2021) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 3 years of Amortization of Deferred Charges data on file, last reported at $115589.0 in Q2 2021.
- Amortization of Deferred Charges for Q2 2021 came in at $115589.0, down 3.68% year-over-year; the trailing twelve-month figure through Jun 2021 was $484647.0 (up 3.64% YoY), and the FY2019 annual result was $452054.0, changed N/A from the prior year.
- Amortization of Deferred Charges slipped to $115589.0 in Q2 2021 per MTNB's latest filing, from $126896.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $126896.0 in Q1 2021 and troughed at $110277.0 in Q1 2019.
- A 3-year average of $117178.9 and a median of $115862.0 in 2019 frame the typical range for Amortization of Deferred Charges.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 7.62% in 2021 and fell as far as 3.68% in 2021.
- A 3-year view of Amortization of Deferred Charges shows it stood at $115862.0 in 2019, then rose by 5.44% to $122162.0 in 2020, then decreased by 5.38% to $115589.0 in 2021.
- Business Quant data shows MTNB's Amortization of Deferred Charges at $115589.0 in Q2 2021, $126896.0 in Q1 2021, and $122162.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 115,589.00 |
| Jun 30, 2021 | 115,589.00 |
| Mar 31, 2021 | 126,896.00 |
| Mar 31, 2021 | 126,896.00 |
| Sep 30, 2020 | 122,162.00 |
| Sep 30, 2020 | 122,162.00 |
| Jun 30, 2020 | 120,000.00 |
| Jun 30, 2020 | 120,000.00 |
| Mar 31, 2020 | 117,909.00 |
| Mar 31, 2020 | 117,909.00 |
| Dec 31, 2019 | 115,862.00 |
| Dec 31, 2019 | 115,862.00 |
| Sep 30, 2019 | 113,872.00 |
| Sep 30, 2019 | 113,872.00 |
| Jun 30, 2019 | 112,043.00 |
| Jun 30, 2019 | 112,043.00 |
| Mar 31, 2019 | 110,277.00 |
| Mar 31, 2019 | 110,277.00 |